0000950170-24-080011.txt : 20240702 0000950170-24-080011.hdr.sgml : 20240702 20240702073000 ACCESSION NUMBER: 0000950170-24-080011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240628 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SeaStar Medical Holding Corp CENTRAL INDEX KEY: 0001831868 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 853681132 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39927 FILM NUMBER: 241092907 BUSINESS ADDRESS: STREET 1: 3513 BRIGHTON BLVD STREET 2: SUITE 410 CITY: DENVER STATE: CO ZIP: 80216 BUSINESS PHONE: 844-427-8100 MAIL ADDRESS: STREET 1: 3513 BRIGHTON BLVD STREET 2: SUITE 410 CITY: DENVER STATE: CO ZIP: 80216 FORMER COMPANY: FORMER CONFORMED NAME: LMF Acquisition Opportunities Inc DATE OF NAME CHANGE: 20201109 8-K 1 icu-20240628.htm 8-K 8-K
0001831868false0001831868us-gaap:CommonStockMember2024-06-282024-06-280001831868icu:WarrantsMember2024-06-282024-06-2800018318682024-06-282024-06-28

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 28, 2024

 

 

SeaStar Medical Holding Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39927

85-3681132

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3513 Brighton Blvd,

Suite 410

 

Denver, Colorado

 

80216

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 844 427-8100

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

 

☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock par value $0.0001 per share

 

ICU

 

The Nasdaq Stock Market LLC

Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share

 

ICUCW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 1.01 Entry Into a Material Definitive Agreement

 

On June 28, 2024, SeaStar Medical Holding Corporation, a Delaware corporation (the “Company”), and an institutional investor (the "Holder"), entered into a warrant redemption agreement (the “Agreement”). Pursuant to the Agreement, the Company agreed to redeem all 126,330 warrants (the “Warrants”) to purchase shares of the Company's common stock, par value $0.0001 per share, owned by the Holder, that were issued by the Company to the Holder, as the holder of certain senior unsecured convertible notes (the "Notes") pursuant to a securities purchase agreement entered into on March 15, 2023, by and between the Company and the Holder (the “Purchase Agreement”) and certain letter agreements in connection therewith.

The Company agreed to pay to the Holder $3.56 per Warrant, for an aggregate redemption price of $449,734.80 (the “Redemption Amount”). The Redemption Amount consists of: (i) $100,000 paid on July 1, 2024 and (ii) $349,734.80 to be paid no later than August 27, 2024, (the “Deferred Payment Amount”). Interest will accrue on the Deferred Payment Amount at a rate of 7.00% per annum, compounded annually.

These warrants were classified as liabilities on the Company's balance sheet due to certain features that precluded equity classification. Pursuant to the Agreement, the Company and the Holder acknowledged and agreed that all covenants, indebtedness, liabilities and other obligations of the Company under or pursuant to the Purchase Agreement, the Notes and the Warrants were satisfied and discharged in full and that the Company has no further obligations, and the Holder has no further rights, relating to the Purchase Agreement, the Notes or the Warrants other than those rights and obligations that expressly survive termination of the Purchase Agreement, the Notes or the Warrants.

The foregoing summary of the Redemption Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Redemption Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 1.02 Termination of a Material Definitive Agreement.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 9.01 - Financial Statements and Exhibits

 

(d) Exhibits

 

 

Exhibit Number

 

Description

Exhibit 10.1

 

Warrant Redemption Agreement, dated June 28, 2024, by and between SeaStar Medical Holding Corporation and an institutional investor.

Exhibit 104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SeaStar Medical Holding Corporation

 

 

By:

/s/ Eric Schlorff

Date:

July 2, 2024

Name:

Eric Schlorff

 

 

Title:

Chief Executive Officer

 

 EX-10.1 2 icu-ex10_1.htm EX-10.1 EX-10.1

Exhibit 10.1

 

WARRANT REDEMPTION AGREEMENT

 

 

June 28, 2024 This Warrant Redemption Agreement (this “Agreement”) is entered into by and between SeaStar Medical Holding Corporation (the “Company”) and 3i, LP or its assigns (the “Holder”). Reference is hereby made to the series of warrants set forth hereto on Annex A (the “Warrants”), to purchase shares of common stock, par value $0.001 per share (“Common Stock”) issued in connection with the issuance by the Company to the Holder of Senior Unsecured Convertible Notes (the “Notes”) pursuant to a Securities Purchase Agreement entered into on March 15, 2023 by and between the Company and the Holder (as amended, the “Agreement”).

 

This Agreement confirms that, in consideration for the Holder’s agreement to redeem all of the outstanding Warrants, such that the Holder will no longer hold any Warrants of the Company following the redemption of the Warrants by the Holder, the Company hereby agrees to pay to the Holder $3.56 per Warrant for a total redemption price of $449,734.80 (the “Redemption Price”). The Redemption Price shall be paid by the Company as follows: (i) $100,000 shall be paid to Holder within one (1) business day of the date hereof and (ii) $349,734.80 (the “Deferred Payment Amount”) shall be paid in full not later than the sixtieth (60) day of the date hereof with interest to accrue on the outstanding and unpaid Deferred Payment Amount at a rate equal to seven percent (7%) per annum, compounded annually.

 

As of the date hereof, the Company and the Holder hereby acknowledge and agree that all covenants, indebtedness, liabilities and other obligations of the Company under or pursuant to the Agreement, the Notes and the Warrants have been satisfied and discharged in full (excluding obligations that by their terms expressly survive termination of the Agreement, the Notes or the Warrants) and that the Company shall have no further obligation to provide the Holder with notice or obtain the Holder’s consent in connection with any transactions contemplated by the Agreement, the Notes or the Warrants. For the avoidance of doubt, from the date hereof, the Company shall have no further obligations, and the Holder shall have no further rights, relating to the Agreement, the Notes or the Warrants, including Section 4.12 of the Agreement, other than those rights and obligations that expressly survive termination of the Agreement, the Notes or the Warrants.

 

 

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

 

SEASTAR MEDICAL HOLDING CORPORATION

 

/s/ Eric Schlorff

Name: Eric Schlorff

Title: Chief Executive Officer

 

 

3i, LP

 

/s/ Maier J. Tarlow

Name: Maier J. Tarlow

Title: Manager on Behalf of the GP

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[SIGNATURE PAGE TO WARRANT AMENDMENT AGREEMENT]

 

 

ANNEX A

 

HOLDER WARRANTS

 

 

Series Warrants

Issue Date

Expiration Date

Total Remaining

Redemption Amount

A-1

3/15/2023

3/14/2028

13,135

$46,760.60

A-2

5/12/2023

5/11/2028

8,757

$31,174.92

A-7

12/11/2023

12/10/2028

21,109

$75,148.04

A-8

1/12/2024

1/11/2029

5,278

$18,789.68

A-9

1/24/2024

1/23/2029

15,832

$56,361.92

AW 1-2024-02

1/24/2024

1/23/2029

15,832

$56,361.92

AW 1-2024-01

1/12/2024

1/11/2029

5,278

$18,789.68

AW 12-2023-01

12/11/2023

12/10/2028

21,109

$75,148.04

SL 08-23-01

8/7/2023

8/7/2028

20,000

$71,200.00

Total

 

 

126,330

$449,734.80

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX A

 EX-101.SCH 3 icu-20240628.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Document Information [Table] Entity Central Index Key Entity Address, State or Province Cover [Abstract] Entity Address, Address Line One Amendment Flag Class of Stock [Domain] Entity Address, City or Town Document Type Title of 12(b) Security Soliciting Material Entity Address, Address Line Two Document Period End Date Trading Symbol Pre-commencement Tender Offer Security Exchange Name Class of Stock [Axis] Written Communications Entity Ex Transition Period Pre-commencement Issuer Tender Offer Warrants. Warrants [Member] Warrants [Member] Entity Registrant Name Entity Emerging Growth Company Entity File Number Entity Tax Identification Number City Area Code Local Phone Number Document Information [Line Items] Common Stock [Member] XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Document And Entity Information
Jun. 28, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 28, 2024
Entity Registrant Name SeaStar Medical Holding Corporation
Entity Central Index Key 0001831868
Entity Emerging Growth Company true
Entity File Number 001-39927
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 85-3681132
Entity Address, Address Line One 3513 Brighton Blvd
Entity Address, Address Line Two Suite 410
Entity Address, City or Town Denver
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80216
City Area Code 844
Local Phone Number 427-8100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock par value $0.0001 per share
Trading Symbol ICU
Security Exchange Name NASDAQ
Warrants [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share
Trading Symbol ICUCW
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports icu-20240628.htm icu-20240628.xsd http://xbrl.sec.gov/dei/2024 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "icu-20240628.htm": { "nsprefix": "icu", "nsuri": "http://seastarmedical.com/20240628", "dts": { "inline": { "local": [ "icu-20240628.htm" ] }, "schema": { "local": [ "icu-20240628.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 27 }, "report": { "R1": { "role": "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_7f9f06da-ec90-431a-baa0-b1a91fbf50c3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "icu-20240628.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_7f9f06da-ec90-431a-baa0-b1a91fbf50c3", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "icu-20240628.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "icu_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://seastarmedical.com/20240628", "localname": "WarrantsMember", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Warrants.", "label": "Warrants [Member]", "terseLabel": "Warrants [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://seastarmedical.com/20240628/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0000950170-24-080011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-080011-xbrl.zip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icu-20240628_htm.xml IDEA: XBRL DOCUMENT 0001831868 us-gaap:CommonStockMember 2024-06-28 2024-06-28 0001831868 icu:WarrantsMember 2024-06-28 2024-06-28 0001831868 2024-06-28 2024-06-28 0001831868 false 8-K 2024-06-28 SeaStar Medical Holding Corporation DE 001-39927 85-3681132 3513 Brighton Blvd Suite 410 Denver CO 80216 844 427-8100 false false false false Common Stock par value $0.0001 per share ICU NASDAQ Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share ICUCW NASDAQ true false